戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 uticasone furoate-vilanterol or umeclidinium-vilanterol).
2 ity issues and was considered as a backup to vilanterol.
3 comes compared with fluticasone-umeclidinium-vilanterol.
4 moterol compared to fluticasone-umeclidinium-vilanterol.
5 r fluticasone furoate (0.90 [0.72-1.11]) and vilanterol (0.99 [0.80-1.22]).
6 asone furoate, HR 0.91 [0.77-1.08]; p=0.284; vilanterol, 0.96 [0.81-1.14]; p=0.655), and therefore se
7 CrI] compared to MD fluticasone/umeclidinium/vilanterol: 0.65 [0.49, 0.89]), while HD BDP/FOR/GLY dem
8 le therapy (fluticasone furoate/umeclidinium/vilanterol 100 mug/62.5 mug/25 mug; ELLIPTA inhaler) wit
9 ong-acting beta2-agonist fluticasone furoate/vilanterol 100/25 mug or placebo (7-day minimum washout)
10 , 2011 and Oct 17, 2011) in which once a day vilanterol 25 mug was compared with 25 mug vilanterol pl
11 aled placebo, fluticasone furoate (100 mug), vilanterol (25 mug), or the combination of fluticasone f
12 ination of fluticasone furoate (100 mug) and vilanterol (25 mug).
13 te and salmeterol or fluticasone furoate and vilanterol); a control arm (not given inhaled fluticason
14 novel once-daily beta2-agonists (olodaterol, vilanterol, abediterol) are under development, mainly in
15 l reduced exacerbations by 29% compared with vilanterol alone (mean 0.91 vs 1.28 exacerbations per pa
16 ion and Medication Ordering System to 25 mug vilanterol alone or 25 mug vilanterol combined with eith
17 icasone furoate and vilanterol compared with vilanterol alone were not associated with eosinophil cou
18                     In patients treated with vilanterol alone, exacerbation rates increased progressi
19 casone furoate and vilanterol, compared with vilanterol alone, were 24% in patients with baseline eos
20 fluticasone furoate and vilanterol than with vilanterol alone.
21  would prevent more exacerbations than would vilanterol alone.
22  patients receiving fluticasone-umeclidinium-vilanterol and an identical incidence of first admission
23 erol, tiotropium-olodaterol, or umeclidinium-vilanterol) and combination ICS-LABA inhalers (budesonid
24     Indacaterol/glycopyrronium, umeclidinium/vilanterol, and olodaterol/tiotropium FDCs have been app
25 bromide/mometasone, fluticasone/umeclidinium/vilanterol, and salmeterol/fluticasone + tiotropium.
26 fluticasone furoate at a dose of 100 mug and vilanterol at a dose of 25 mug (the fluticasone furoate-
27 olate-formoterol or fluticasone-umeclidinium-vilanterol between 1 January 2021 and 30 September 2023
28  System to 25 mug vilanterol alone or 25 mug vilanterol combined with either 50 mug, 100 mug, or 200
29 ther prescribing of fluticasone-umeclidinium-vilanterol compared with budesonide-glycopyrrolate-formo
30 sk of pneumonia with fluticasone furoate and vilanterol compared with vilanterol alone were not assoc
31 ients initiated with fluticasone furoate and vilanterol, compared with 2.8 points in the usual care g
32 n exacerbations with fluticasone furoate and vilanterol, compared with vilanterol alone, were 24% in
33 e furoate, and the long-acting beta agonist, vilanterol could improve survival compared with placebo
34 risk, treatment with fluticasone furoate and vilanterol did not affect mortality or cardiovascular ou
35 erence 8 mL per year [95% CI 1-14]), but not vilanterol (difference -2 mL per year [95% CI -8 to 5]).
36 ) risk with fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with
37 d between the 200/25 mug fluticasone furoate/vilanterol group and the vilanterol only group (mean 0.9
38 [71%] of 1373 in the fluticasone furoate and vilanterol group vs 784 [56%] of 1399 in the usual care
39 the fluticasone furoate group, and 4% in the vilanterol group) or adverse cardiac events (17% in the
40 at a dose of 25 mug (the fluticasone furoate-vilanterol group) or to usual care (the usual-care group
41 he fluticasone furoate group, and 17% in the vilanterol group) were noted in the treatment groups.
42 n the fluticasone furoate group, 4118 in the vilanterol group, and 4121 in the combination group.
43 ents of pneumonia in the fluticasone furoate-vilanterol group.
44 umonia were noted in the fluticasone furoate/vilanterol groups compared with none in the vilanterol o
45 ations were noted in all fluticasone furoate/vilanterol groups than in the vilanterol only group (0.0
46 ations were noted in all fluticasone furoate/vilanterol groups than in the vilanterol only group (p=0
47 o usual care, 602 to fluticasone furoate and vilanterol) had a baseline ACT score greater than or equ
48  regimen of combined fluticasone furoate and vilanterol improved asthma control without increasing th
49 ual long-acting bronchodilator (umeclidinium-vilanterol n=2070).
50 um-vilanterol n=4151 and fluticasone furoate-vilanterol n=4134) in reducing rates of moderate and sev
51 aining ICS (fluticasone furoate-umeclidinium-vilanterol n=4151 and fluticasone furoate-vilanterol n=4
52 tiate treatment with fluticasone furoate and vilanterol (n=2114) or usual care (n=2119).
53               New once-daily LABA, including vilanterol, olodaterol, milveterol, carmoterol, and abed
54 casone furoate/vilanterol groups than in the vilanterol only group (0.0141 for the 50 mug group, <0.0
55 fluticasone furoate/vilanterol group and the vilanterol only group (mean 0.90 events vs 1.05 events p
56 casone furoate/vilanterol groups than in the vilanterol only group (p=0.0398 for the 50 mug group, 0.
57 /vilanterol groups compared with none in the vilanterol only group.
58 g or 200 mug fluticasone furoate with 25 mug vilanterol or optimised usual care and followed up for 1
59 th dual inhaled therapy (fluticasone furoate-vilanterol or umeclidinium-vilanterol).
60 moterol, fluticasone-salmeterol, fluticasone-vilanterol, or mometasone-formoterol).
61 y vilanterol 25 mug was compared with 25 mug vilanterol plus 50 mug, 100 mug, or 200 mug fluticasone
62 led corticosteroids, fluticasone furoate and vilanterol reduced exacerbations by 29% compared with vi
63                          Fluticasone furoate/vilanterol safety profile was similar to placebo.
64 casone furoate, alone or in combination with vilanterol, seemed to reduce FEV1 decline.
65 iated treatment with fluticasone furoate and vilanterol than for those on usual care (977 [71%] of 13
66 more frequently with fluticasone furoate and vilanterol than with vilanterol alone.
67 rval, 1.1 to 15.2), with fluticasone furoate-vilanterol therapy than with usual care (P=0.02).
68 more, the triple therapy versus umeclidinium-vilanterol treatment difference was 40 mL (95% CI 10 to
69  in residual volume with fluticasone furoate/vilanterol versus placebo.
70 esponding rate ratio for fluticasone furoate-vilanterol versus umeclidinium-vilanterol was 1.09 (0.91
71 (FF) and long-acting beta(2) -agonist (LABA) vilanterol (VI) on early and late asthmatic responses (E
72 fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) significantly reduced exacerbations comp
73 icacy and safety of umeclidinium (UMEC) plus vilanterol (VI) with tiotropium (TIO) monotherapy, UMEC
74  placebo, fluticasone furoate (FF; 100 mug), vilanterol (VI; 25 mug), or the combination of FF/VI was
75 ratio for triple therapy versus umeclidinium-vilanterol was 0.88 (95% CI 0.74 to 1.04) at blood eosin
76 asone furoate-vilanterol versus umeclidinium-vilanterol was 1.09 (0.91 to 1.29) and 0.56 (0.47 to 0.6
77           Addition of fluticasone furoate to vilanterol was associated with a decreased rate of moder
78  regimen of combined fluticasone furoate and vilanterol was associated with a lower rate of exacerbat
79                                  Fluticasone-vilanterol was introduced, but there was little improvem
80 le therapy (fluticasone furoate-umeclidinium-vilanterol) with dual inhaled therapy (fluticasone furoa
81 We hypothesised that fluticasone furoate and vilanterol would prevent more exacerbations than would v